ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last161 to 180 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Ovarian Screening vs Control: Deaths From All Causes3,508 of 34,253

3,542 of 34,304

-0.1 points

-0.5 to 0.4

68,557NCT01696994

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

Intervention vs Control Arm: deaths from any cause608 of 43,054

380 of 25,088

-0.1 points

-0.3 to 0.1

68,142NCT04570371

Non-pharmacological Pain Management After Surgery

Intervention vs Control Arm: serious adverse events104 of 43,054

25 of 25,088

0.1 points

0.1 to 0.2

68,142NCT04570371

Non-pharmacological Pain Management After Surgery

RotaTeq™ vs Placebo: Intussusception Within 42 Days Following Any Dose of RotaTeq™/Placebo6 of 34,002

5 of 33,969

0.0 points

-0.0 to 0.0

67,971NCT00090233

Rotavirus Efficacy and Safety Trial (REST)(V260-006)

Azithro vs Placebo: deaths from any cause1,493 of 33,173

1,584 of 33,055

-0.3 points

-0.6 to 0.0

66,228NCT03338244

Mortality Reduction After Oral Azithromycin Contingency: Mortality Study

PCV13-vaccinated Participants vs Unvaccinated Participants: VE for First Event of ACP at 5-7 Years of Follow-up1,200 of 25,890

1,757 of 40,301

0.3 points

-0.0 to 0.6

66,191NCT05794191

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

Olodaterol vs Other Long-acting beta2-agonist (LABAs): deaths from any cause859 of 14,239

1,872 of 51,167

2.4 points

2.0 to 2.8

65,406NCT03405363

Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists

Text-Messaging (TM) vs Text-Messaging Plus Patient Navigation: Uptake-Total14,308 of 32,594

14,381 of 32,706

-0.1 points

-0.8 to 0.7

65,300NCT04939519

SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers

Text-Messaging (TM) vs Text-Messaging Plus Patient Navigation: Reach-TM Engage5,538 of 32,594

5,587 of 32,706

-0.1 points

-0.7 to 0.5

65,300NCT04939519

SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers

SMART-AI vs Usual Care: Proportion of Patients That Had a Universal Screen Positive and Received SBIRT (Screening, Brief Intervention, or Referral to Treatment)1,144 of 33,564

1,189 of 31,432

-0.4 points

-0.7 to -0.1

64,996NCT03833804

Data-driven Identification for Substance Misuse

SMART-AI vs Usual Care: All-cause Re-hospitalizations Following 6-months From the Index Hospital Encounter10,241 of 33,564

9,584 of 31,432

0.0 points

-0.7 to 0.7

64,996NCT03833804

Data-driven Identification for Substance Misuse

Anesthesia Control Tower Monitoring vs Standard of Care Arm: Blood Glucose Management1,848 of 32,437

1,786 of 32,435

0.2 points

-0.2 to 0.5

64,872NCT03923699

Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety

Hp Stool Antigen (HpSA)+FIT vs FIT Only: Incidence of Stomach Cancer49 of 31,497

59 of 31,777

-0.0 points

-0.1 to 0.0

63,274NCT01741363

Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing

Hp Stool Antigen (HpSA)+FIT vs FIT Only: Mortality of Stomach Cancer17 of 31,497

23 of 31,777

-0.0 points

-0.1 to 0.0

63,274NCT01741363

Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing

Standardized Intervention vs Control: deaths from any cause599 of 31,493

582 of 31,519

0.1 points

-0.2 to 0.3

63,012NCT02621476

Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities

Empagliflozin Initiators vs Dipeptidyl Peptidate-4 Inhibitor (DPP4i) Initiators: deaths from any cause341 of 20,279

1,528 of 41,918

-2.0 points

-2.2 to -1.7

62,197NCT05465317

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

LNG IUS vs Copper IUD: Contraceptive Failure26 of 43,078

92 of 18,370

-0.4 points

-0.6 to -0.3

61,448NCT00461175

European Active Surveillance Study for Intrauterine Devices

LNG IUS vs Copper IUD: Uterine Perforation Rate61 of 43,078

20 of 18,370

0.0 points

-0.0 to 0.1

61,448NCT00461175

European Active Surveillance Study for Intrauterine Devices

LNG IUS vs Copper IUD: serious adverse events21 of 43,078

7 of 18,370

0.0 points

-0.0 to 0.0

61,448NCT00461175

European Active Surveillance Study for Intrauterine Devices

CONCERN Intervention Group vs Usual Care Group: deaths from any cause181 of 33,024

265 of 27,869

-0.4 points

-0.5 to -0.3

60,893NCT03911687

(CONCERN) Clinical Decision Support (CDS) System

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=9

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01696994-f8dc1c23",
        "title": "Ovarian Screening vs Control: Deaths From All Causes",
        "summary": "3508 of 34253 against 3542 of 34304; risk difference -0.1 points, 95% interval -0.5 to 0.4; NCT01696994, Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)",
        "record": "/library/comparisons/NCT01696994-f8dc1c23",
        "nct_id": "NCT01696994",
        "kind": "outcome",
        "participants": 68557,
        "risk_difference": {
          "value": -0.000838877864385773,
          "lower": -0.005386793512808159,
          "upper": 0.003709083948153502
        },
        "group_1": "3,508 of 34,253",
        "group_2": "3,542 of 34,304",
        "difference": "-0.1 points",
        "interval": "-0.5 to 0.4",
        "trial_title": "Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)"
      },
      {
        "id": "NCT04570371-deaths",
        "title": "Intervention vs Control Arm: deaths from any cause",
        "summary": "608 of 43054 against 380 of 25088; risk difference -0.1 points, 95% interval -0.3 to 0.1; NCT04570371, Non-pharmacological Pain Management After Surgery",
        "record": "/library/comparisons/NCT04570371-deaths",
        "nct_id": "NCT04570371",
        "kind": "deaths",
        "participants": 68142,
        "risk_difference": {
          "value": -0.0010248831439018669,
          "lower": -0.002940236605468309,
          "upper": 0.0008224731664002714
        },
        "group_1": "608 of 43,054",
        "group_2": "380 of 25,088",
        "difference": "-0.1 points",
        "interval": "-0.3 to 0.1",
        "trial_title": "Non-pharmacological Pain Management After Surgery"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=10",
  "request_id": "Luy9gACJM4Tw2aRv"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?